Unethical practices - drug industry
Steven B. Harris
sbharris at ix.netcom.com
Tue Aug 29 01:37:17 EST 1995
In <41tiat$e0i at parsifal.nando.net> "John W. Barron"
<jwbarron at nando.net> writes:
>May I humbly suggest that you go back and do a little history
>Tagamet and H. pylori involvement discovery did not occur at the same
>time. Is it fair to go back and examine sales, and sales promotion
>practices which pre-dated a significant scientific discovery, which
>even today is not completely accepted by many involved in ulcer
>diagnosis and therapy.
>Also, to my knowledge, Tagamet was never designed or marketed as a
>"cure" for ulcers. That was to a great extent responsible for the
>constantly growing sales picture. Every person put on the drug
>remained a constant purchaser.
>BTW, how about market competition? Didn't Tagamet have a little?
>Did Tagamet remain the most prescribed prescription medication
>after Glaxo began their promotional activity?
>It is very easy to point to our pharmaceutical industry and sling
>arrows at its faults. But, please list for me the drugs that have
>been successfully developed and used in the U.S. which came
>from non-industry sources, such as universities, NIH, etc.
>I would very much like to have such a list. I think the other
>readers would profit from such information, also.
>John W. Barron, Pharm. D.
>email: jwbarron at nando.net
Tagamet demonstrably saved a HUGE number of people from gastectomy
for bleeding ulcers, a costly proceedure which carries a
not-insignicant mortality risk. It's a drug that more than paid for
itself in social expenses for disease, even if it was something of a
stop-gap treatment. As you say, hindsight is 20-20.
Steve Harris, M.D.
More information about the Neur-sci